MedDataX Logo

VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients

NCT ID: NCT00561925

Last Updated: 2014-04-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1068 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate the efficacy of 400 mg QD nevirapine extended release (NVP XR) formulation versus 200 mg BID nevirapine immediate release (NVP IR) in ARV therapy naïve HIV-1 infected patients after 48 weeks of treatment. Secondary objectives are to evaluate safety and pharmacokinetics of NVP XR and NVP IR.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients

NCT00819052

HIV Infections
COMPLETED PHASE3

Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects

NCT02194179

HIV Infections
COMPLETED PHASE1

Observational Non-interventional Study With Viramune® in Combination With Truvada® in HIV-infected Patients

NCT00543803

HIV Infections
COMPLETED

Pharmacokinetic Interaction Between Nevirapine and Saquinavir-sgc in HIV-1 Infected Patients

NCT02184286

HIV Infections
TERMINATED PHASE1

The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine

NCT00002381

HIV Infections
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

nevirapine XR

400 mg QD

Group Type EXPERIMENTAL

nevirapine XR

Intervention Type DRUG

400 mg QD

nevirapine IR

200 mg BID

Group Type ACTIVE_COMPARATOR

nevirapine IR

Intervention Type DRUG

200 mg BID

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nevirapine IR

200 mg BID

Intervention Type DRUG

nevirapine XR

400 mg QD

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed informed consent in accordance with Good Clinical Practice and local regulatory requirements prior to trial participation
2. HIV-1 infected males or females \>= 18 years of age with positive serology (ELISA) confirmed by Western blot
3. No previous antiretroviral treatment
4. Males with CD4+ counts \>50 - \<400 cells/ml or females with CD4+ counts \>50-\<250 cells/ml
5. Adequate renal function defined as a calculated creatinine clearance (CLCr) greater than or equal to 50 mL/min according to the Cockcroft-Gault formula as follows:

Male: (140 - age in years) x (weight in kg) divided by 72 x (serum creatinine in mg/dl) = CLCr (mL/min).

Female: (140 - age in years) x (weight in kg) divided by 72 x (serum creatinine in mg/dl) x 0.85 = CLCr (mL/min).
6. Karnofsky score \>70 (see Appendix 10.4)
7. An HIV-1 viral load of 1,000 copies/mL
8. Willingness to initiate CD4+ cell count-guided chemoprophylaxis to prevent important opportunistic infections as defined in Appendix 10.2
9. Willingness to abstain from ingesting substances which may alter plasma study drug levels by interaction with the cytochrome P450 system (listed in Appendix 10.3) during the study.
10. For centers participating in the PK substudy only: Written informed consent in accordance with GCP and local legislation for participation in the PK substudy. Refusal to participate in the PK substudy is not an exclusion criterion for participation in the trial. Only study centers with previous experience and equipped in handling PK samples are eligible for participation in the substudy.

Exclusion Criteria

1. Active drug abuse or chronic alcoholism at the investigator's discretion
2. Active hepatitis B or C disease, defined as HBsAg-positive and HBV-DNA-positive or HCV-RNA-positive
3. Female patients of child-bearing potential who: are pregnant at screening; are breast feeding; are planning to become pregnant; are not willing to use a barrier method of contraception, or; are not willing to use methods of contraception other than ethinyl estradiol containing oral contraceptives Note: During participation in this study, females and males have to use barrier methods of contraception in addition or instead of ethinyl estradiol containing oral contraceptives.
4. Laboratory parameters \>DAIDS Grade 2
5. ALT/AST \> DAIDS Grade 1
6. Hypersensitivity to any ingredients of the test products
7. Previous use of Viramune® (nevirapine) or any other antiretroviral agents (does not include use of single dose NVP for the prevention of mother to child transmission)
8. Resistance to NNRTIs or either one of the components of Truvada® (emtricitabine or tenofovir disoproxil fumarate) or lamivudine (3TC) based on HIV-1 genotypic resistance testing report obtained at screening
9. Patients who are receiving other concomitant treatments which are not permitted, as described in the prescribing information
10. Use of investigational medications (any experimental agent other than the study regimen) within 30 days before study entry or during the trial
11. Use of immunomodulatory drugs within 30 days before study entry or during the trial (e.g., interferon, cyclosporin, hydroxyurea, interleukin 2)
12. Patients who have been diagnosed with malignant disease
13. Patients who in the opinion of the investigator are not candidates for inclusion in the study
14. Patient with Progressive Multifocal Leukoencephalopathy (PML), Visceral Kaposi's Sarcoma (KS), and/or any lymphoma
15. Any AIDS defining illness that is unresolved, symptomatic or not stable on treatment for at least 12 weeks at screening visit
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1100.1486.0040 Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

Site Status

1100.1486.0013 Boehringer Ingelheim Investigational Site

Phoenix, Arizona, United States

Site Status

1100.1486.0017 Boehringer Ingelheim Investigational Site

Bakersfield, California, United States

Site Status

1100.1486.0001 Boehringer Ingelheim Investigational Site

Beverly Hills, California, United States

Site Status

1100.1486.0057 Boehringer Ingelheim Investigational Site

Beverly Hills, California, United States

Site Status

1100.1486.0059 Boehringer Ingelheim Investigational Site

Beverly Hills, California, United States

Site Status

1100.1486.0035 Boehringer Ingelheim Investigational Site

Long Beach, California, United States

Site Status

1100.1486.0025 Boehringer Ingelheim Investigational Site

Los Angeles, California, United States

Site Status

1100.1486.0034 Boehringer Ingelheim Investigational Site

Los Angeles, California, United States

Site Status

1100.1486.0041 Boehringer Ingelheim Investigational Site

Los Angeles, California, United States

Site Status

1100.1486.0032 Boehringer Ingelheim Investigational Site

Sacramento, California, United States

Site Status

1100.1486.0028 Boehringer Ingelheim Investigational Site

San Diego, California, United States

Site Status

1100.1486.0023 Boehringer Ingelheim Investigational Site

Washington D.C., District of Columbia, United States

Site Status

1100.1486.0029 Boehringer Ingelheim Investigational Site

Washington D.C., District of Columbia, United States

Site Status

1100.1486.0048 Boehringer Ingelheim Investigational Site

Washington D.C., District of Columbia, United States

Site Status

1100.1486.0037 Boehringer Ingelheim Investigational Site

Clearwater, Florida, United States

Site Status

1100.1486.0043 Boehringer Ingelheim Investigational Site

Fort Lauderdale, Florida, United States

Site Status

1100.1486.0012 Boehringer Ingelheim Investigational Site

Miami, Florida, United States

Site Status

1100.1486.0007 Boehringer Ingelheim Investigational Site

Miami Beach, Florida, United States

Site Status

1100.1486.0039 Boehringer Ingelheim Investigational Site

Orlando, Florida, United States

Site Status

1100.1486.0050 Boehringer Ingelheim Investigational Site

Vero Beach, Florida, United States

Site Status

1100.1486.0014 Boehringer Ingelheim Investigational Site

Wilton Manors, Florida, United States

Site Status

1100.1486.0031 Boehringer Ingelheim Investigational Site

Atlanta, Georgia, United States

Site Status

1100.1486.0010 Boehringer Ingelheim Investigational Site

Macon, Georgia, United States

Site Status

1100.1486.0053 Boehringer Ingelheim Investigational Site

Boise, Idaho, United States

Site Status

1100.1486.0002 Boehringer Ingelheim Investigational Site

Chicago, Illinois, United States

Site Status

1100.1486.0026 Boehringer Ingelheim Investigational Site

Chicago, Illinois, United States

Site Status

1100.1486.0020 Boehringer Ingelheim Investigational Site

Lexington, Kentucky, United States

Site Status

1100.1486.0019 Boehringer Ingelheim Investigational Site

Berkley, Michigan, United States

Site Status

1100.1486.0006 Boehringer Ingelheim Investigational Site

Kansas City, Missouri, United States

Site Status

1100.1486.0027 Boehringer Ingelheim Investigational Site

St Louis, Missouri, United States

Site Status

1100.1486.0055 Boehringer Ingelheim Investigational Site

Charlotte, North Carolina, United States

Site Status

1100.1486.0003 Boehringer Ingelheim Investigational Site

Huntersville, North Carolina, United States

Site Status

1100.1486.0005 Boehringer Ingelheim Investigational Site

Akron, Ohio, United States

Site Status

1100.1486.0004 Boehringer Ingelheim Investigational Site

Austin, Texas, United States

Site Status

1100.1486.0018 Boehringer Ingelheim Investigational Site

Dallas, Texas, United States

Site Status

1100.1486.0038 Boehringer Ingelheim Investigational Site

Dallas, Texas, United States

Site Status

1100.1486.0044 Boehringer Ingelheim Investigational Site

Fort Worth, Texas, United States

Site Status

1100.1486.0054 Boehringer Ingelheim Investigational Site

Harlingen, Texas, United States

Site Status

1100.1486.0009 Boehringer Ingelheim Investigational Site

Houston, Texas, United States

Site Status

1100.1486.0046 Boehringer Ingelheim Investigational Site

Annandale, Virginia, United States

Site Status

1100.1486.5401 Boehringer Ingelheim Investigational Site

Capital Federal, , Argentina

Site Status

1100.1486.5402 Boehringer Ingelheim Investigational Site

Capital Federal, , Argentina

Site Status

1100.1486.5404 Boehringer Ingelheim Investigational Site

Capital Federal, , Argentina

Site Status

1100.1486.5407 Boehringer Ingelheim Investigational Site

Capital Federal, , Argentina

Site Status

1100.1486.5408 Boehringer Ingelheim Investigational Site

Capital Federal, , Argentina

Site Status

1100.1486.5403 Boehringer Ingelheim Investigational Site

Mar del Plata, , Argentina

Site Status

1100.1486.5409 Boehringer Ingelheim Investigational Site

Quilmes, , Argentina

Site Status

1100.1486.5405 Boehringer Ingelheim Investigational Site

Rosario, , Argentina

Site Status

1100.1486.6101 Boehringer Ingelheim Investigational Site

Darlinghurst, New South Wales, Australia

Site Status

1100.1486.6102 Boehringer Ingelheim Investigational Site

Darlinghurst, New South Wales, Australia

Site Status

1100.1486.6104 Boehringer Ingelheim Investigational Site

Surry Hills, New South Wales, Australia

Site Status

1100.1486.6103 Boehringer Ingelheim Investigational Site

Brisbane, Queensland, Australia

Site Status

1100.1486.3208 Boehringer Ingelheim Investigational Site

Bruges, , Belgium

Site Status

1100.1486.3201 Boehringer Ingelheim Investigational Site

Brussels, , Belgium

Site Status

1100.1486.3203 Boehringer Ingelheim Investigational Site

Brussels, , Belgium

Site Status

1100.1486.3205 Boehringer Ingelheim Investigational Site

Brussels, , Belgium

Site Status

1100.1486.3207 Boehringer Ingelheim Investigational Site

Brussels, , Belgium

Site Status

1100.1486.3209 Boehringer Ingelheim Investigational Site

Charleroi, , Belgium

Site Status

1100.1486.3202 Boehringer Ingelheim Investigational Site

Ghent, , Belgium

Site Status

1100.1486.3204 Boehringer Ingelheim Investigational Site

Liège, , Belgium

Site Status

1100.1486.3206 Boehringer Ingelheim Investigational Site

Liège, , Belgium

Site Status

1100.1486.2605 Boehringer Ingelheim Investigational Site

Francistown, , Botswana

Site Status

1100.1486.2601 Boehringer Ingelheim Investigational Site

Gaborone, , Botswana

Site Status

1100.1486.2603 Boehringer Ingelheim Investigational Site

Gaborone, , Botswana

Site Status

1100.1486.1002 Boehringer Ingelheim Investigational Site

Vancouver, British Columbia, Canada

Site Status

1100.1486.1004 Boehringer Ingelheim Investigational Site

Winnipeg, Manitoba, Canada

Site Status

1100.1486.1013 Boehringer Ingelheim Investigational Site

Toronto, Ontario, Canada

Site Status

1100.1486.1016 Boehringer Ingelheim Investigational Site

Toronto, Ontario, Canada

Site Status

1100.1486.1005 Boehringer Ingelheim Investigational Site

Montreal, Quebec, Canada

Site Status

1100.1486.1010 Boehringer Ingelheim Investigational Site

Montreal, Quebec, Canada

Site Status

1100.1486.1014 Boehringer Ingelheim Investigational Site

Montreal, Quebec, Canada

Site Status

1100.1486.1011 Boehringer Ingelheim Investigational Site

Quebec (Ste Foy), Quebec, Canada

Site Status

1100.1486.3305A Boehringer Ingelheim Investigational Site

Angers, , France

Site Status

1100.1486.3305B Boehringer Ingelheim Investigational Site

Angers, , France

Site Status

1100.1486.3307A Boehringer Ingelheim Investigational Site

Bondy, , France

Site Status

1100.1486.3317A Boehringer Ingelheim Investigational Site

Bordeaux, , France

Site Status

1100.1486.3316A Boehringer Ingelheim Investigational Site

Brest, , France

Site Status

1100.1486.3316B Boehringer Ingelheim Investigational Site

Brest, , France

Site Status

1100.1486.3314E Boehringer Ingelheim Investigational Site

Caen, , France

Site Status

1100.1486.3304A Boehringer Ingelheim Investigational Site

Clamart, , France

Site Status

1100.1486.3308A Boehringer Ingelheim Investigational Site

Lyon, , France

Site Status

1100.1486.3308C Boehringer Ingelheim Investigational Site

Lyon, , France

Site Status

1100.1486.3301A Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

1100.1486.3301B Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

1100.1486.3301C Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

1100.1486.3301D Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

1100.1486.3301E Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

1100.1486.3301F Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

1100.1486.3301G Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

1100.1486.3301H Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

1100.1486.3301I Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

1100.1486.3306A Boehringer Ingelheim Investigational Site

Nice, , France

Site Status

1100.1486.3303A Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

1100.1486.3303B Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

1100.1486.3303C Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

1100.1486.3303D Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

1100.1486.3312A Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

1100.1486.3312B Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

1100.1486.3309A Boehringer Ingelheim Investigational Site

Saint-Etienne, , France

Site Status

1100.1486.3309B Boehringer Ingelheim Investigational Site

Saint-Etienne, , France

Site Status

1100.1486.3318A Boehringer Ingelheim Investigational Site

Toulon, , France

Site Status

1100.1486.3318B Boehringer Ingelheim Investigational Site

Toulon, , France

Site Status

1100.1486.3318C Boehringer Ingelheim Investigational Site

Toulon, , France

Site Status

1100.1486.3318D Boehringer Ingelheim Investigational Site

Toulon, , France

Site Status

1100.1486.3302A Boehringer Ingelheim Investigational Site

Toulouse, , France

Site Status

1100.1486.3302B Boehringer Ingelheim Investigational Site

Toulouse, , France

Site Status

1100.1486.3302C Boehringer Ingelheim Investigational Site

Toulouse, , France

Site Status

1100.1486.3310A Boehringer Ingelheim Investigational Site

Villeneuve-Saint-Georges, , France

Site Status

1100.1486.4902 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

1100.1486.4928 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

1100.1486.4932 Boehringer Ingelheim Investigational Site

Bochum, , Germany

Site Status

1100.1486.4922 Boehringer Ingelheim Investigational Site

Bonn, , Germany

Site Status

1100.1486.4907 Boehringer Ingelheim Investigational Site

Cologne, , Germany

Site Status

1100.1486.4924 Boehringer Ingelheim Investigational Site

Cologne, , Germany

Site Status

1100.1486.4911 Boehringer Ingelheim Investigational Site

Dortmund, , Germany

Site Status

1100.1486.4919 Boehringer Ingelheim Investigational Site

Düsseldorf, , Germany

Site Status

1100.1486.4908 Boehringer Ingelheim Investigational Site

Erlangen, , Germany

Site Status

1100.1486.4906 Boehringer Ingelheim Investigational Site

Essen, , Germany

Site Status

1100.1486.4926 Boehringer Ingelheim Investigational Site

Frankfurt, , Germany

Site Status

1100.1486.4916 Boehringer Ingelheim Investigational Site

Frankfurt am Main, , Germany

Site Status

1100.1486.4929 Boehringer Ingelheim Investigational Site

Frankfurt am Main, , Germany

Site Status

1100.1486.4901 Boehringer Ingelheim Investigational Site

Freiburg im Breisgau, , Germany

Site Status

1100.1486.4930 Boehringer Ingelheim Investigational Site

Freiburg im Breisgau, , Germany

Site Status

1100.1486.4909 Boehringer Ingelheim Investigational Site

Hamburg, , Germany

Site Status

1100.1486.4920 Boehringer Ingelheim Investigational Site

Hamburg, , Germany

Site Status

1100.1486.4925 Boehringer Ingelheim Investigational Site

Hamburg, , Germany

Site Status

1100.1486.4915 Boehringer Ingelheim Investigational Site

Hanover, , Germany

Site Status

1100.1486.4923 Boehringer Ingelheim Investigational Site

Hanover, , Germany

Site Status

1100.1486.4910 Boehringer Ingelheim Investigational Site

Kiel, , Germany

Site Status

1100.1486.4927 Boehringer Ingelheim Investigational Site

Mainz, , Germany

Site Status

1100.1486.4903 Boehringer Ingelheim Investigational Site

München, , Germany

Site Status

1100.1486.4904 Boehringer Ingelheim Investigational Site

München, , Germany

Site Status

1100.1486.4912 Boehringer Ingelheim Investigational Site

München, , Germany

Site Status

1100.1486.4905 Boehringer Ingelheim Investigational Site

Münster, , Germany

Site Status

1100.1486.4918 Boehringer Ingelheim Investigational Site

Osnabrück, , Germany

Site Status

1100.1486.4913 Boehringer Ingelheim Investigational Site

Ulm/Donau, , Germany

Site Status

1100.1486.4914 Boehringer Ingelheim Investigational Site

Würzburg, , Germany

Site Status

1100.1486.3531 Boehringer Ingelheim Investigational Site

Dublin, , Ireland

Site Status

1100.1486.3532 Boehringer Ingelheim Investigational Site

Dublin, , Ireland

Site Status

1100.1486.3908 Boehringer Ingelheim Investigational Site

Palermo, , Italy

Site Status

1100.1486.3905 Boehringer Ingelheim Investigational Site

Pescara, , Italy

Site Status

1100.1486.3901 Boehringer Ingelheim Investigational Site

Torino, , Italy

Site Status

1100.1486.3907 Boehringer Ingelheim Investigational Site

Treviso, , Italy

Site Status

1100.1486.3906 Boehringer Ingelheim Investigational Site

Verbania, , Italy

Site Status

1100.1486.5207 Boehringer Ingelheim Investigational Site

Guadalajara, , Mexico

Site Status

1100.1486.5204 Boehringer Ingelheim Investigational Site

León, , Mexico

Site Status

1100.1486.3107 Boehringer Ingelheim Investigational Site

Amsterdam, , Netherlands

Site Status

1100.1486.3103 Boehringer Ingelheim Investigational Site

Arnhem, , Netherlands

Site Status

1100.1486.3101 Boehringer Ingelheim Investigational Site

Rotterdam, , Netherlands

Site Status

1100.1486.3102 Boehringer Ingelheim Investigational Site

Zwolle, , Netherlands

Site Status

1100.1486.4803 Boehringer Ingelheim Investigational Site

Bydgoszcz, , Poland

Site Status

1100.1486.4801 Boehringer Ingelheim Investigational Site

Chorzów, , Poland

Site Status

1100.1486.4804 Boehringer Ingelheim Investigational Site

Warsaw, , Poland

Site Status

1100.1486.3503 Boehringer Ingelheim Investigational Site

Amadora, , Portugal

Site Status

1100.1486.3501 Boehringer Ingelheim Investigational Site

Lisbon, , Portugal

Site Status

1100.1486.3504 Boehringer Ingelheim Investigational Site

Lisbon, , Portugal

Site Status

1100.1486.0024 Boehringer Ingelheim Investigational Site

Ponce, , Puerto Rico

Site Status

1100.1486.0033 Boehringer Ingelheim Investigational Site

San Juan, , Puerto Rico

Site Status

1100.1486.4001 Boehringer Ingelheim Investigational Site

Bucharest, , Romania

Site Status

1100.1486.4002 Boehringer Ingelheim Investigational Site

Bucharest, , Romania

Site Status

1100.1486.7002 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1100.1486.7001 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

1100.1486.2707 Boehringer Ingelheim Investigational Site

Bloemfontein, , South Africa

Site Status

1100.1486.2712 Boehringer Ingelheim Investigational Site

Bloemfontein, , South Africa

Site Status

1100.1486.2703 Boehringer Ingelheim Investigational Site

Cape Town, , South Africa

Site Status

1100.1486.2709 Boehringer Ingelheim Investigational Site

Cape Town, , South Africa

Site Status

1100.1486.2711 Boehringer Ingelheim Investigational Site

Cape Town, , South Africa

Site Status

1100.1486.2701 Boehringer Ingelheim Investigational Site

Edenvale, , South Africa

Site Status

1100.1486.2710 Boehringer Ingelheim Investigational Site

Johannesburg, , South Africa

Site Status

1100.1486.2706 Boehringer Ingelheim Investigational Site

Mbombela, , South Africa

Site Status

1100.1486.2702 Boehringer Ingelheim Investigational Site

Port Elizabeth, , South Africa

Site Status

1100.1486.2704 Boehringer Ingelheim Investigational Site

Pretoria, , South Africa

Site Status

1100.1486.3406 Boehringer Ingelheim Investigational Site

Alcalá de Henares (Madrid), , Spain

Site Status

1100.1486.3401 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

1100.1486.3402 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

1100.1486.3410 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

1100.1486.3415 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

1100.1486.3417 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

1100.1486.3404 Boehringer Ingelheim Investigational Site

L'Hospitalet de Llobregat, , Spain

Site Status

1100.1486.3403 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1100.1486.3405 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1100.1486.3407 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1100.1486.3414 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1100.1486.3416 Boehringer Ingelheim Investigational Site

Mataró, , Spain

Site Status

1100.1486.3408 Boehringer Ingelheim Investigational Site

Valencia, , Spain

Site Status

1100.1486.4101 Boehringer Ingelheim Investigational Site

Basel, , Switzerland

Site Status

1100.1486.4109 Boehringer Ingelheim Investigational Site

Bern, , Switzerland

Site Status

1100.1486.4107 Boehringer Ingelheim Investigational Site

Geneva, , Switzerland

Site Status

1100.1486.4106 Boehringer Ingelheim Investigational Site

La Chaux-de-Fonds, , Switzerland

Site Status

1100.1486.4104 Boehringer Ingelheim Investigational Site

Lausanne, , Switzerland

Site Status

1100.1486.4102 Boehringer Ingelheim Investigational Site

Lugano, , Switzerland

Site Status

1100.1486.4108 Boehringer Ingelheim Investigational Site

Sankt Gallen, , Switzerland

Site Status

1100.1486.4110 Boehringer Ingelheim Investigational Site

Zurich, , Switzerland

Site Status

1100.1486.4406 Boehringer Ingelheim Investigational Site

Birmingham, , United Kingdom

Site Status

1100.1486.4403 Boehringer Ingelheim Investigational Site

London, , United Kingdom

Site Status

1100.1486.4404 Boehringer Ingelheim Investigational Site

London, , United Kingdom

Site Status

1100.1486.4405 Boehringer Ingelheim Investigational Site

London, , United Kingdom

Site Status

1100.1486.4407 Boehringer Ingelheim Investigational Site

London, , United Kingdom

Site Status

1100.1486.4401 Boehringer Ingelheim Investigational Site

Manchester, , United Kingdom

Site Status

1100.1486.4408 Boehringer Ingelheim Investigational Site

Manchester, , United Kingdom

Site Status

1100.1486.4402 Boehringer Ingelheim Investigational Site

Plaistow, London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Belgium Botswana Canada France Germany Ireland Italy Mexico Netherlands Poland Portugal Puerto Rico Romania Russia South Africa Spain Switzerland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Gathe J, Andrade-Villanueva J, Santiago S, Horban A, Nelson M, Cahn P, Bogner J, Spencer D, Podzamczer D, Yong CL, Nguyen T, Zhang W, Drulak M, Quinson AM. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients. Antivir Ther. 2011;16(5):759-69. doi: 10.3851/IMP1803.

Reference Type DERIVED
PMID: 21817198 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2007-003654-29

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1100.1486

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Multiple Dose BE Study With Nevirapine 400mg PR Tablets
NCT02202005 COMPLETED PHASE1
A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.
NCT00905489 COMPLETED PHASE1
Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults
NCT02182765 TERMINATED PHASE1
Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*
NCT00511368 COMPLETED PHASE2
The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients
NCT00000962 COMPLETED PHASE1
Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients
NCT00876733 COMPLETED
Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients
NCT02184299 COMPLETED PHASE4
An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.
NCT00002194 COMPLETED PHASE1
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
NCT00002418 TERMINATED PHASE2
Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ Patients
NCT02184078 COMPLETED PHASE4
A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive
NCT00002215 COMPLETED NA
The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs
NCT00002368 COMPLETED PHASE3
A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1
NCT06061081 TERMINATED PHASE2
A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments
NCT00006211 COMPLETED PHASE2
Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048
NCT02419456 COMPLETED PHASE1
A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine
NCT00344461 COMPLETED PHASE4
VENICE Study Nevirapine Full Dose/Dose Escalation
NCT00704249 COMPLETED PHASE4
KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects
NCT00549198 COMPLETED PHASE4
Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive Patients
NCT00199979 UNKNOWN PHASE3
An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3
NCT00000747 COMPLETED PHASE2
Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048
NCT02356302 COMPLETED PHASE1
An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)
NCT00000649 COMPLETED PHASE1
The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease
NCT00002324 COMPLETED PHASE2
Case-Control Viramune (Nevirapine) Toxicogenomics Study
NCT00310843 COMPLETED
A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell
NCT00002323 COMPLETED NA